KIR2DL4 (2DL4;CD158d) is a structurally and functionally unique member of the human killer cell Ig-like receptor (KIR) family. It can interact with HLA-G, which is normally expressed on trophoblast cells. In contrast to other KIR, engagement of 2DL4 can stimulate potent cytokine responses, but only weak cytotoxicity by freshly isolated NK cells. 2DL4 is only expressed on CD56high NK cells in peripheral blood, and is the only KIR that can be up-regulated upon culture in IL-2. The mechanisms regulating expression and function of 2DL4 remain poorly understood. Interestingly, common alleles of the 2DL4 gene encode proteins that cannot reach the surface of NK cells, and as many as 25% of the human population are homozygous for non-expressed alleles. This suggests that these individuals may lack physiologically important innate immune responses that may make them more or less susceptible to certain disease states. We have established that the unique activating properties of 2DL4 are mediated through two distinct signaling modules that are dependent or independent of physical association with the Fc?RI-? signaling adaptor. Furthermore, we have recently discovered that 2DL4 can associate with an important kinase and an E3 ubiquitin ligase that can mediate and regulate receptor function, respectively. Finally, we have evidence for a novel ligand expressed on transformed epithelial and fibroblast cell lines that has potential to engage 2DL4 at sites of cancer or inflammation. We propose to define the molecular basis by which KIR2DL4 can activate distinct functional response programs in NK cells, which may occur when they encounter trophoblasts, tumor cells, or inflammatory sites by pursuing the following specific aims:
Aim 1. How does an E3 ubiquitin ligase regulate KIR2DL4 expression and function? Aim 2. What is the mechanism of Fc?RI-?-independent signaling by KIR2DL4? Aim 3. Characterization of novel KIR2DL4 ligand(s) on transformed epithelial and fibroblast cells

Public Health Relevance

KIR2DL4 is an activating receptor on human natural killer (NK) cells that can stimulate innate immune cytokine responses. Surprisingly, genetic polymorphisms prevent a large proportion of the human population from expressing this receptor on the NK cell surface, which may make them uniquely susceptible to certain disease states. Therefore, our studies of the ligands that engage with KIR2DL4 and molecular mechanisms controlling its function and expression are essential for establishing its role in human health and disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
High Priority, Short Term Project Award (R56)
Project #
2R56CA100226-06A1
Application #
7870559
Study Section
Innate Immunity and Inflammation Study Section (III)
Program Officer
Howcroft, Thomas K
Project Start
2003-04-01
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2012-06-30
Support Year
6
Fiscal Year
2009
Total Cost
$279,491
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Brusilovsky, Michael; Cordoba, Moti; Rosental, Benyamin et al. (2013) Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses. J Immunol 191:5256-67
Miah, S M Shahjahan; Purdy, Amanda K; Rodin, Nicholas B et al. (2011) Ubiquitylation of an internalized killer cell Ig-like receptor by Triad3A disrupts sustained NF-?B signaling. J Immunol 186:2959-69
Borghaei, Hossein; Smith, Mitchell R; Campbell, Kerry S (2009) Immunotherapy of cancer. Eur J Pharmacol 625:41-54
Purdy, Amanda K; Campbell, Kerry S (2009) Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 8:2211-20